CN108261423B - 用于加工含有活细胞的生物药物的方法 - Google Patents

用于加工含有活细胞的生物药物的方法 Download PDF

Info

Publication number
CN108261423B
CN108261423B CN201810178504.0A CN201810178504A CN108261423B CN 108261423 B CN108261423 B CN 108261423B CN 201810178504 A CN201810178504 A CN 201810178504A CN 108261423 B CN108261423 B CN 108261423B
Authority
CN
China
Prior art keywords
cells
hours
cell
formulation
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810178504.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108261423A (zh
Inventor
迈克尔·哈-诺伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovative Therapies Ltd
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of CN108261423A publication Critical patent/CN108261423A/zh
Application granted granted Critical
Publication of CN108261423B publication Critical patent/CN108261423B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
    • A01N1/148—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving with provisions specially adapted for transporting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Mechanical Engineering (AREA)
  • Dermatology (AREA)
CN201810178504.0A 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法 Active CN108261423B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161481991P 2011-05-03 2011-05-03
US61/481,991 2011-05-03
US201161528493P 2011-08-29 2011-08-29
US61/528,493 2011-08-29
US201161565225P 2011-11-30 2011-11-30
US61/565,225 2011-11-30
US201261582878P 2012-01-04 2012-01-04
US61/582,878 2012-01-04
CN201280032760.XA CN103732247A (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280032760.XA Division CN103732247A (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法

Publications (2)

Publication Number Publication Date
CN108261423A CN108261423A (zh) 2018-07-10
CN108261423B true CN108261423B (zh) 2021-01-08

Family

ID=47108026

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280032760.XA Pending CN103732247A (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法
CN201810178504.0A Active CN108261423B (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201280032760.XA Pending CN103732247A (zh) 2011-05-03 2012-05-02 用于加工含有活细胞的生物药物的方法

Country Status (17)

Country Link
US (4) US10350242B2 (enExample)
EP (1) EP2704741B1 (enExample)
JP (3) JP5934783B2 (enExample)
KR (3) KR102202460B1 (enExample)
CN (2) CN103732247A (enExample)
AU (1) AU2012250794B2 (enExample)
BR (1) BR112013028257B1 (enExample)
CA (1) CA2838041C (enExample)
DK (1) DK2704741T3 (enExample)
ES (1) ES2648136T3 (enExample)
HU (1) HUE034995T2 (enExample)
IL (1) IL229176B (enExample)
PH (1) PH12013502253A1 (enExample)
PL (1) PL2704741T3 (enExample)
PT (1) PT2704741T (enExample)
SG (1) SG194774A1 (enExample)
WO (1) WO2012151266A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160095307A1 (en) * 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
WO2016075542A1 (en) * 2014-11-11 2016-05-19 Macrocure, Ltd. Methods for extended storage of activated leukocyte compositions
JP6814593B2 (ja) * 2016-10-14 2021-01-20 株式会社 バイオミメティクスシンパシーズ 幹細胞及び投与システム
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
SG11202106053SA (en) * 2018-12-07 2021-07-29 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for immunotherapy
CA3137570A1 (en) * 2019-05-15 2020-11-19 Stemcyte Inc. High concentration cell packaging and shipping
WO2022124307A1 (ja) 2020-12-10 2022-06-16 Ａｇｃ株式会社 オキシアルキレン重合体、その製造方法、硬化性組成物、硬化物
EP4306570A4 (en) 2021-03-12 2025-03-05 Agc Inc. HARDENABLE COMPOSITION AND HARDENED PRODUCT
EP4368671A4 (en) 2021-07-07 2025-07-16 Agc Inc CURABLE COMPOSITION, CURED PRODUCT, ADHESIVE AND SEALANT
WO2023190640A1 (ja) * 2022-03-30 2023-10-05 株式会社カネカ 細胞投与用シリンジを調製する方法、及び細胞投与用シリンジを用いた細胞輸送方法
DE112023002002T5 (de) 2022-04-22 2025-02-20 AGC Inc. Aushärtbare zusammensetzung und ausgehärtetes produkt davon
DE112023002011T5 (de) 2022-04-22 2025-02-20 AGC Inc. Aushärtbare zusammensetzung und ausgehärtetes produkt
CN119072501A (zh) 2022-04-27 2024-12-03 Ａｇｃ株式会社 含反应性硅基团的有机聚合物的制造方法
WO2023210582A1 (ja) 2022-04-27 2023-11-02 Ａｇｃ株式会社 反応性ケイ素基含有有機重合体の製造方法
JPWO2023233962A1 (enExample) 2022-06-03 2023-12-07

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
EP1792979A1 (en) * 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2439003A1 (fr) 1978-10-20 1980-05-16 Anvar Nouvelles pieces d'osteosynthese, leur preparation et leur application
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
ZA888978B (en) 1987-12-04 1990-07-25 Du Pont Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6204058B1 (en) 1992-02-07 2001-03-20 Vasogen Ireland Limited Treatment of autoimmune diseases
WO1994012196A1 (en) 1992-11-25 1994-06-09 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
WO1995004817A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
IL107483A0 (en) 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
PT814838E (pt) 1995-03-08 2003-09-30 Scripps Research Inst Sistema de apresentacao de antigenio e activacao de celulas t
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
DE69737070T2 (de) 1996-05-23 2007-06-21 The Scripps Research Institute, La Jolla Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
DE69718029T2 (de) * 1996-10-11 2003-10-16 The Regents Of The University Of California, Oakland Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
AU5596898A (en) 1996-12-03 1998-06-29 Osteobiologics, Inc. Biodegradable polymeric film
WO1998033891A1 (en) 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
US7282198B2 (en) 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
DE69840171D1 (de) 1997-05-30 2008-12-11 Osteobiologics Inc Faserverstärkte,poröse,biologisch abbaubare implantatvorrichtung
JP2001522806A (ja) 1997-11-10 2001-11-20 アーチ・デヴェロップメント・コーポレイション エクス・ビボ活性化ｔ細胞を用いる腫瘍および腫瘍細胞の処理方法
AU4518400A (en) 1999-07-12 2001-01-18 Isotis B.V. Sutures
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
HK1047770A1 (zh) 2000-02-24 2003-03-07 Xcyte Therapies, Inc. 细胞的同时刺激与浓缩
AU2001292564A1 (en) 2000-08-31 2002-03-13 Emory University A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
AU2002342299A1 (en) 2001-10-31 2003-05-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Generation of use of tc1 and tc2 cells
WO2003053216A2 (en) 2001-12-06 2003-07-03 University Of Washington Biodegradable, porous structures useful for growing living tissue, and methods of manufacture
US20030170238A1 (en) * 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7371228B2 (en) 2003-09-19 2008-05-13 Medtronic Vascular, Inc. Delivery of therapeutics to treat aneurysms
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
DK2573166T3 (da) 2004-02-26 2016-07-04 Immunovative Therapies Ltd Fremgangsmåder til fremstilling af T-celler til celleterapi
US7446099B2 (en) 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection
HUE035726T2 (en) 2004-03-01 2018-05-28 Immunovative Therapies Ltd Cell therapy formulation method and composition
CA2557436A1 (en) 2004-03-05 2005-09-29 The Trustees Of Columbia University In The City Of New York Polymer-ceramic-hydrogel composite scaffold for osteochondral repair
TW200726474A (en) * 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
BRPI0909780B1 (pt) * 2008-03-05 2022-05-03 Baxter International Inc Suspensão contendo uma partícula com superfície modificada, composição farmacêutica compreendendo a referida suspensão, método para aprimorar a absorção celular de um agente ativo, uso de partículas com superfície modificada, e método de preparação de uma partícula com superfície modificada

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
EP1792979A1 (en) * 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Effect storage of granulocytes collected by celltrifugation leukapheresis from donors stimulated with granulocyte-colony-stimlating factor;Hubel K等;《Transfusion》;20051231;第45卷(第12期);1876-1889 *
Overnight storage of aulologous stem cell apheresis products before cryopreservation dose not adversely impact early or long-term engraftment following transplantation;RARKINS MD等;《Bone Marrow Transplantation》;20060918;第38卷(第9期);609-614 *

Also Published As

Publication number Publication date
CA2838041C (en) 2018-09-25
BR112013028257A2 (pt) 2017-01-17
US10350242B2 (en) 2019-07-16
EP2704741A4 (en) 2014-11-19
CN108261423A (zh) 2018-07-10
AU2012250794B2 (en) 2015-11-05
JP2017039728A (ja) 2017-02-23
US11648273B2 (en) 2023-05-16
US20190350976A1 (en) 2019-11-21
PT2704741T (pt) 2017-11-24
CN103732247A (zh) 2014-04-16
BR112013028257B1 (pt) 2020-05-12
KR20140099328A (ko) 2014-08-11
JP2015091848A (ja) 2015-05-14
WO2012151266A1 (en) 2012-11-08
KR102229108B1 (ko) 2021-03-18
US20230218672A1 (en) 2023-07-13
AU2012250794A1 (en) 2013-12-12
PH12013502253A1 (en) 2019-11-29
JP2014517830A (ja) 2014-07-24
AU2012250794A8 (en) 2013-12-19
KR20140043367A (ko) 2014-04-09
US20130101562A1 (en) 2013-04-25
JP6359059B2 (ja) 2018-07-18
SG194774A1 (en) 2013-12-30
IL229176B (en) 2020-03-31
ES2648136T3 (es) 2017-12-28
KR20190090030A (ko) 2019-07-31
EP2704741A1 (en) 2014-03-12
EP2704741B1 (en) 2017-08-23
JP5934783B2 (ja) 2016-06-15
CA2838041A1 (en) 2012-11-08
DK2704741T3 (da) 2017-11-27
JP6006288B2 (ja) 2016-10-12
IL229176A0 (en) 2013-12-31
HUE034995T2 (en) 2018-05-02
PL2704741T3 (pl) 2018-02-28
US20230226112A1 (en) 2023-07-20
HK1254754A1 (zh) 2019-07-26
KR102202460B1 (ko) 2021-01-14

Similar Documents

Publication Publication Date Title
CN108261423B (zh) 用于加工含有活细胞的生物药物的方法
US20220387497A1 (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
ES2675317T3 (es) Expansión de linfocitos T reguladores reactivos a aloantígeno
US20100233192A1 (en) Manufacturing Method of Activated Lymphocytes for Immunotherapy
EP2925329B1 (en) Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
CN117616115A (zh) 一种修饰的肿瘤浸润淋巴细胞及其用途
HK1195873A (en) Methods for handling biological drugs containing living cells
TWI682996B (zh) 處理含有活細胞之生物藥物的方法
HK1254754B (zh) 用於加工含有活细胞的生物药物的方法
WO2020196297A1 (ja) 免疫細胞提供方法
McEwen et al. Regulatory T cell therapy in transplantation
US20150150910A1 (en) Substitute therapy for glucocorticoids
AU2011231558A2 (en) Substitute therapy for glucocorticoids

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254754

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant